NCT02879851

Brief Summary

The study aims at quantifying the registration error obtained in routine patients in different parts of the prostate and for operators with different experience in order to assess the average precision of the elastic MR-ultrasound fusion obtained by Koelis™ system. Patients referred for placement of intraprostatic fiducials before radiotherapy for prostate cancer will be prospectively offered to enter the study. The fiducials will be placed under transrectal ultrasound guidance, in the prostate apex, midgland and base, according to our routine procedure. A 3D Ultrasound acquisition of the prostate will be obtained at the end of the placement. As per our routine procedure, patients will undergo unenhanced prostate MRI to control the position of the fiducials. An elastic fusion of the MR images and the 3D ultrasound acquisitions will be retrospectively performed by operators of varying experience using the Koelis system. The fiducials (visible on MR and ultrasound images) will be used to quantify the registration error.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

August 9, 2016

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 26, 2016

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Last Updated

August 26, 2016

Status Verified

August 1, 2016

Enrollment Period

2.9 years

First QC Date

August 9, 2016

Last Update Submit

August 22, 2016

Conditions

Keywords

ultrasoundKoelis systemMRIgold grain

Outcome Measures

Primary Outcomes (1)

  • Accuracy of the overall registration obtained by the Koelis™ system

    The fusion will be performed retrospectively without interfering with patient management. This fusion is an off-line analysis that will be performed within one month of the images acquisition. Each of the four operators will perform a US/MR fusion for all patients and will be blinded to the fusions performed by the others. The results will be presented when all operators have finished the fusions in all patients. The overall registration error (TRE3D, defined as the Euclidean distance between the US marker and the MR marker after fusion) will be calculated based on the 3D coordinates of the fiducials on MR and ultrasound images.

    1 month

Secondary Outcomes (2)

  • Influence on TRE3D of the position of the fiducials (apex, midgland and base)

    1 month

  • Influence on TRE3D of the experience of the fusion operators

    1 month

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with prostate cancer referred for placement of intraprostatic fiducials before prostate radiotherapy

You may qualify if:

  • Age ≥ 18 years
  • Patient requiring placement of intraprostatic fiducials
  • No contra-indication for fiducials placement
  • No contra -indication to MRI
  • No contra -indication for intravenous injection of gadolinium chelates
  • Patient affiliated to the social security system
  • Patients who received oral and written information

You may not qualify if:

  • Patient deprived of liberty as a result of a judicial or administrative decision.
  • Patient under guardianship or curatorship.
  • Any event preventing or prematurely interrupting the collection of assessment criteria would result in the premature exit of the subject.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital of Edouard Herriot

Lyon, 69003, France

RECRUITING

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Central Study Contacts

Olivier ROUVIERE, Professor

CONTACT

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2016

First Posted

August 26, 2016

Study Start

January 1, 2015

Primary Completion

December 1, 2017

Last Updated

August 26, 2016

Record last verified: 2016-08

Locations